<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-KEN25055-82G-KM-8YL"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 S355 IS: FDA Modernization Act 3.0</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-02-03</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 355</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250203">February 3, 2025</action-date><action-desc><sponsor name-id="S370">Mr. Booker</sponsor> (for himself, <cosponsor name-id="S420">Mr. Schmitt</cosponsor>, <cosponsor name-id="S363">Mr. King</cosponsor>, <cosponsor name-id="S389">Mr. Kennedy</cosponsor>, <cosponsor name-id="S316">Mr. Whitehouse</cosponsor>, <cosponsor name-id="S411">Mr. Marshall</cosponsor>, <cosponsor name-id="S341">Mr. Blumenthal</cosponsor>, <cosponsor name-id="S348">Mr. Paul</cosponsor>, and <cosponsor name-id="S409">Mr. Luján</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods.</official-title></form><legis-body><section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>FDA Modernization Act 3.0</short-title></quote>.</text></section><section id="idc0c513ac68664020a34035d96402026a"><enum>2.</enum><header>Regulations on nonclinical testing methods</header><subsection id="id32eebb6fb1bf46cc92da4a6873ad2444"><enum>(a)</enum><header>Interim final rule</header><paragraph commented="no" display-inline="no-display-inline" id="id5c0c67af5e16431b910a7fcbf7b27764"><enum>(1)</enum><header display-inline="yes-display-inline">In general</header><text>Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall publish an interim final rule pursuant to subsections (b) and (c) to ensure implementation of the amendments to section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) made by section 3209(a) of the Consolidated Appropriations Act, 2023 (<external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>; 136 Stat. 5821).</text></paragraph><paragraph id="id2ca763eb22974753a38688f82e04bdb4"><enum>(2)</enum><header>Effectiveness of interim final rule</header><text>Notwithstanding subparagraph (B) of section 553(b) of title 5, United States Code, the interim final rule issued by the Secretary of Health and Human Services under paragraph (1) shall become immediately effective as an interim final rule without requiring the Secretary of Health and Human Services to demonstrate good cause therefor. </text></paragraph></subsection><subsection id="id76f918ccff984bea8f24d2b429338b83"><enum>(b)</enum><header>Inclusions</header><paragraph commented="no" display-inline="no-display-inline" id="id7780590faf6643d79410b40d94052073"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The interim final rule shall replace any references to <quote>animal</quote> tests, data, studies, models, and research with a reference to nonclinical tests, data, studies, models, and research in the following sections of title 21, Code of Federal Regulations:</text><subparagraph id="ida54894d204584e8cbd09c2eb08e1d635"><enum>(A)</enum><text>Section 312.22(c).</text></subparagraph><subparagraph id="id187777049170416a9fbcaca162e7c48b"><enum>(B)</enum><text>Section 312.23(a)(3)(iv).</text></subparagraph><subparagraph id="id2d8d7b9ff86441978754114d7fcc81c0"><enum>(C)</enum><text>Section 312.23(a)(5)(ii).</text></subparagraph><subparagraph id="id2d7b1ff4c46f495f95fb4fbe4e749138"><enum>(D)</enum><text>Section 312.23(a)(5)(iii).</text></subparagraph><subparagraph id="id075349bf8e1342168cd6d3140482a090"><enum>(E)</enum><text>Section 312.23(a)(8).</text></subparagraph><subparagraph id="id4cf66f8e27544d0ea40c6149a7cd3da1"><enum>(F)</enum><text>Section 312.23(a)(8)(i).</text></subparagraph><subparagraph id="id4f898d0a697d4ae3ae54153ea94613e7"><enum>(G)</enum><text>Section 312.23(a)(8)(ii).</text></subparagraph><subparagraph id="id7c6f694d12ed4d1fb0bf4f10979ac4a6"><enum>(H)</enum><text>Section 312.23(a)(10)(i).</text></subparagraph><subparagraph id="id3ae8213733ef414fbfe1319d0b05226c"><enum>(I)</enum><text>Section 312.23(a)(10)(ii).</text></subparagraph><subparagraph id="ide7c65fd5218f4c518d72c0e1e7b5040f"><enum>(J)</enum><text>Section 312.33(b)(6).</text></subparagraph><subparagraph id="id3e79523a9456442689d8796f2b1bea2f"><enum>(K)</enum><text>Section 312.82(a).</text></subparagraph><subparagraph id="id41ee250f99f246e9948956b28dd72dd9"><enum>(L)</enum><text>Section 312.88.</text></subparagraph><subparagraph id="id4d3bb4b686104a80a9006af3cfb93070"><enum>(M)</enum><text>Section 314.50(d)(2).</text></subparagraph><subparagraph id="id3b2242f148a44d5cbd8b5a70aa9109aa"><enum>(N)</enum><text>Section 314.50(d)(2)(iv).</text></subparagraph><subparagraph id="id27593af1db5d4ced8de4b7997408aade"><enum>(O)</enum><text>Section 314.50(d)(5)(i).</text></subparagraph><subparagraph id="idcff4b0ee4c064ae985f3a67f83c98e19"><enum>(P)</enum><text>Section 314.50(d)(5)(vi)(a).</text></subparagraph><subparagraph id="id7080370ba3244faba849801e9dd40231"><enum>(Q)</enum><text>Section 314.50(d)(5)(vi)(b).</text></subparagraph><subparagraph id="id99b64180b3a640aeb38219303140b7d6"><enum>(R)</enum><text>Section 314.93(e)(2).</text></subparagraph><subparagraph id="id246b1d68daeb497ba18617841ede3e11"><enum>(S)</enum><text>Section 315.6(d).</text></subparagraph><subparagraph id="id6aad89faed62443bbc27d07a58e72ca2"><enum>(T)</enum><text>Section 330.10(a)(2).</text></subparagraph><subparagraph id="id191aae4b2bfd42da91f0471e01de78cb"><enum>(U)</enum><text>Section 601.35(d).</text></subparagraph><subparagraph id="id02a50c5b9bde421cb8e3b3cc55e953f0"><enum>(V)</enum><text>Any other section necessary to ensure regulatory consistency with the amendments to section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) made by section 3209(a) of the Consolidated Appropriations Act, 2023 (<external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>; 136 Stat. 5821). </text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id617dfd85032e48cfb3201adf19d27df8"><enum>(2)</enum><header>Additional changes</header><text display-inline="yes-display-inline">The Secretary may make such additional changes to the sections of title 21, Code of Federal Regulations, described in subparagraphs (A) through (V) of paragraph (1) as the Secretary determines appropriate to fully implement the replacement required under such paragraph.</text></paragraph></subsection><subsection id="id500ae61dcb564fcabe5c32ad7ecd89c5"><enum>(c)</enum><header>Definition of nonclinical test</header><text>The definition of <term>nonclinical test</term> in section 505(z) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(z)</external-xref>) shall be added to sections 312.3, 314.3, 315.2, and 601.31 of title 21, Code of Federal Regulations.</text></subsection><subsection id="id13e2f46eb2f04813ab0655eee67226ae" commented="no" display-inline="no-display-inline"><enum>(d)</enum><header>Technical amendment</header><text>Section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) is amended by designating the second subsection (z) (relating to clinical trial diversity action plans), as added by section 3601(a) of the Health Extenders, Improving Access to Medicare, Medicaid, and CHIP, and Strengthening Public Health Act of 2022 (division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>), as subsection (aa). </text></subsection></section></legis-body></bill> 

